Business
ORIC Pharmaceuticals Reports First Quarter 2023 Financial Results and Operational Updates
Initial Phase 1b data for three ongoing clinical trials expected in second half of 2023: ORIC-533 in multiple myeloma, ORIC-114 in EGFR/HER2-mutated cancers,
About this update from Oric Pharmaceuticals, Inc.
[{"type":"text","content":"Initial Phase 1b data for three ongoing clinical trials expected in second half of 2023: ORIC-533 in multiple myeloma, ORIC-114 in EGFR/HER2-mutated cancers, and ORIC-944 in prostate cancer Preclinical data for ORIC-944 and PLK4 program presented at the 2023 AACR Annual Meeting Cash and investments of $208.9 million expected to fund operating plan into first half of 2025 SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, May 08, 2023 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today reported financial results and operational updates for the quarter ended March 31, 2023. “We continue to execute and make strong progress in advancing our novel oncology pipeline,” said Jacob M. Chacko, MD, chief executive officer. “At the 2023 AACR meeting, we presented promising preclinical data highlighting our comprehensive biomarker strategy for ORIC-944, our allosteric PRC2 inhibitor, and preclinical data for our PLK4 program, demonstrating the potential of highly selective PLK4 inhibition as a synthetic lethal approach for TRIM37 amplified cancers. Our three clinical programs are enrolling steadily and we look forward to reporting initial clinical data from our ongoing studies in the second half of 2023.” First Quarter 2023 and Other Recent Highlights ORIC-533: a highly potent, orally bioavailable small molecule inhibitor of CD73 Enrolling a Phase 1b trial of ORIC-533 as a single-agent, in patients with relapsed/refractory multiple myeloma.Expect to report initial Phase 1b data for ORIC-533 in the second half of 2023. ORIC-114: a brain penetrant, orally bioavailable, irreversible EGFR/HER2 inhibitor Enrolling a Phase 1b trial of ORIC-114 as a single-agent, in patients with advanced solid tumors with EGFR and HER2 exon 20 alterations or HER2 amplifications, including patients with CNS metastases that are either treated or untreated but asymptomatic.Expect to report initial Phase 1b data for ORIC-114 in the second half of 2023. ORIC-944: a potent and selective allosteric inhibitor of PRC2 Enrolling a Phase 1b trial of ORIC-944 as a single-agent, in patients with advanced prostate cancer.Presented preclinical data highlighting a comprehensive biomarker strategy for the ongoing Phase 1b trial in metastatic prostate cance...